| |
Significant patient populations, top clinical institutions, and ease of
regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠
|
|
Today's Big NewsOct 28, 2022 |
| By Nick Paul Taylor The dream of taming IL-2 keeps slipping further away. After seeing Bristol Myers Squibb and Nektar Therapeutics give up on their candidate, Sanofi has reported “lower than projected” efficacy data on its prospect and rethought its plans for the molecule. |
|
|
|
By Nick Paul Taylor Vultures are circling Quantum Genomics. A high-stakes phase 3 hypertension readout has gone against the French biotech, prompting it to stop work on firibastat in cardiology and reallocate its remaining 11 million euros ($11 million) to other projects. |
By Max Bayer A new STAT News investigation has found that Eisai's experimental Alzheimer's drug lecenemab may have contributed to a patient's death, according to documents obtained by the outlet. The Japanese pharma acknowledged the death but wouldn't divulge specific details citing patient privacy. |
By Gabrielle Masson An increasingly bitter conflict between biotech and investor has come to a close, with Mereo BioPharma losing out to Rubric Capital Management and handing the activist investor four spots on its board. |
By Helen Floersh Evidence is growing that insulin resistance drives Alzheimer’s development, and several medications used to treat diabetes are in clinical trials to see if they can combat the condition. Now, new findings about the way insulin is delivered to the brain suggest that it’s worth looking into a broader range of diabetes drugs than previously thought. |
By Querida Anderson This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
By Max Bayer,Gabrielle Masson Frazier is leaving Merck after 30 years, handing the executive chairman role to CEO Davis. GSK's vaccine chief is departing amid a restructuring of the medicine and vaccine units. CRISPR development head Klein leaves as the company nears its first regulatory filing. |
By Andrea Park Months after its G7 continuous glucose monitor landed European approval in March—leading to a wide-scale rollout of the sensor across the continent earlier this month—Dexcom is zeroing in on the U.S. market. |
By Angus Liu Over a year after the FDA’s dreaded boxed warning addition and treatment line demotion, the JAK inhibitor class of inflammatory disease drugs has gotten its uses restricted by European regulators as well out of safety concerns. |
By Dave Muoio CMS said it was loosening vaccination requirements and noncompliance citation severity for certain healthcare facilities due to "relatively low" COVID-19 hospitalizations and deaths across the nation. |
By Ben Adams Endo has certainly captured the public's imagination with its Peyronie's disease (PD) campaigns before—think wonky veg—but this time, it’s playing it straight. |
By Angus Liu Sumitomo has persuaded Myovant into an acquisition that values the latter at $2.9 billion. Astellas is doubling down in gene therapy with a $50 million investment in Taysha Gene Therapies. A couple in a trade secret theft case involving Roche's Genentech and Taiwanese firm JHL Biotech have received six months in prison. And more. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we dig into rumors of a shaky relationship between Biogen and Eisai. We also chat about AZ’s ability to finally tout the approval of an asset that’s seen many failures over the years. |
|
|---|
|
|
|
Wednesday, November 2, 2022 | 1pm ET / 10am PT This webinar will discuss how Invitae and others are working together to characterize the lived experience of patients with rare bile duct cancer, and ultimately, improve patient care. Register now.
|
|
| VideoRevolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
